Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?
Pancreatic cancer is a devastating disease. It is the fourth leading cause of cancer-related death in Germany. The incidence in 2003/2004 was 16 cases per 100.000 inhabitants. Of all carcinomas, pancreatic cancer has the highest mortality rate, with one- and five-year survival rates of 25% and less...
Main Authors: | Robert Grutzmann, Hans Detlev Saeger, Christian Pilarsky, Daniel Zips, Gunnar Folprecht, Carolin Zimmermann |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/3/2/2286/ |
Similar Items
-
Neoadjuvant treatment for pancreatic cancer: Controversies and advances
by: Douglas Dias e Silva, et al.
Published: (2024-01-01) -
Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01) -
Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer
by: Yuhui Huang, et al.
Published: (2022-08-01) -
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation
by: Alisha R. Pershad, et al.
Published: (2024-04-01) -
Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma
by: Wade Christopher, et al.
Published: (2022-12-01)